Home›Tezacaftor And Ivacaftor

Tezacaftor And Ivacaftor

Also known as: Symdeko

Check Tezacaftor And Ivacaftor Interactions →

16 interactions on record

Tezacaftor And Ivacaftor has 16 known drug interactions based on U.S. FDA drug labeling data. 11 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Clarithromycin, Itraconazole. Patients taking Tezacaftor And Ivacaftor should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 16
Major: 11
Moderate: 3
Minor: 1

Major (11)

Tezacaftor And Ivacaftor + Carbamazepine— Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.
Tezacaftor And Ivacaftor + Clarithromycin— Strong CYP3A inhibitor. Co-administration requires dosage adjustment of SYMDEKO.
Tezacaftor And Ivacaftor + Itraconazole— Strong CYP3A inhibitor. Increased tezacaftor exposure 4.0-fold and ivacaftor 15.6-fold; dosage adjustment required.
Tezacaftor And Ivacaftor + Phenobarbital— Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.
Tezacaftor And Ivacaftor + Phenytoin— Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.
Tezacaftor And Ivacaftor + Posaconazole— Strong CYP3A inhibitor. Co-administration requires dosage reduction of SYMDEKO due to increased drug exposure.
Tezacaftor And Ivacaftor + Rifabutin— Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.
Tezacaftor And Ivacaftor + Rifampin— Strong CYP3A inducer. Significantly decreased ivacaftor exposure by 89%; co-administration not recommended due to reduce…
Tezacaftor And Ivacaftor + St. John'S Wort— Strong CYP3A inducer (Hypericum perforatum). Co-administration not recommended due to reduced SYMDEKO efficacy.
Tezacaftor And Ivacaftor + Telithromycin— Strong CYP3A inhibitor. Co-administration requires dosage adjustment of SYMDEKO.
Tezacaftor And Ivacaftor + Voriconazole— Strong CYP3A inhibitor. Co-administration requires dosage reduction of SYMDEKO due to increased drug exposure.

Moderate (3)

Tezacaftor And Ivacaftor + Erythromycin— Examples of moderate CYP3A inhibitors include: fluconazole erythromycin Co-administration of SYMDEKO with grapefruit jui…
Tezacaftor And Ivacaftor + Fluconazole— 7 DRUG INTERACTIONS Potential for other drugs to affect tezacaftor/ivacaftor CYP3A inhibitors: Reduce SYMDEKO dosage whe…
Tezacaftor And Ivacaftor + Ketoconazole— 7 DRUG INTERACTIONS Potential for other drugs to affect tezacaftor/ivacaftor CYP3A inhibitors: Reduce SYMDEKO dosage whe…

Minor (1)

Tezacaftor And Ivacaftor + Ciprofloxacin— No significant effect on tezacaftor or ivacaftor exposure; no dosage adjustment necessary.

Tezacaftor And Ivacaftor + Carbamazepine⚠️Major

Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.

Tezacaftor And Ivacaftor + Clarithromycin⚠️Major

Strong CYP3A inhibitor. Co-administration requires dosage adjustment of SYMDEKO.

Tezacaftor And Ivacaftor + Itraconazole⚠️Major

Strong CYP3A inhibitor. Increased tezacaftor exposure 4.0-fold and ivacaftor 15.6-fold; dosage adjustment required.

Tezacaftor And Ivacaftor + Phenobarbital⚠️Major

Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.

Tezacaftor And Ivacaftor + Phenytoin⚠️Major

Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.

Tezacaftor And Ivacaftor + Posaconazole⚠️Major

Strong CYP3A inhibitor. Co-administration requires dosage reduction of SYMDEKO due to increased drug exposure.

Tezacaftor And Ivacaftor + Rifabutin⚠️Major

Strong CYP3A inducer. Co-administration not recommended due to reduced SYMDEKO efficacy.

Tezacaftor And Ivacaftor + Rifampin⚠️Major

Strong CYP3A inducer. Significantly decreased ivacaftor exposure by 89%; co-administration not recommended due to reduced SYMDEKO efficacy.

Tezacaftor And Ivacaftor + St. John'S Wort⚠️Major

Strong CYP3A inducer (Hypericum perforatum). Co-administration not recommended due to reduced SYMDEKO efficacy.

Tezacaftor And Ivacaftor + Telithromycin⚠️Major

Strong CYP3A inhibitor. Co-administration requires dosage adjustment of SYMDEKO.

Tezacaftor And Ivacaftor + Voriconazole⚠️Major

Strong CYP3A inhibitor. Co-administration requires dosage reduction of SYMDEKO due to increased drug exposure.

Tezacaftor And Ivacaftor + Erythromycin🟡Moderate

Examples of moderate CYP3A inhibitors include: fluconazole erythromycin Co-administration of SYMDEKO with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure of tezacaftor and ivacaftor; therefore, food or drink containing grapefruit should be avoided during treatment with SYMDEKO [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) , and Patient Counseling Information (17) ] .

Tezacaftor And Ivacaftor + Fluconazole🟡Moderate

7 DRUG INTERACTIONS Potential for other drugs to affect tezacaftor/ivacaftor CYP3A inhibitors: Reduce SYMDEKO dosage when co-administered with strong (e.g., ketoconazole) or moderate (e.g., fluconazole) CYP3A inhibitors. Examples of strong CYP3A inhibitors include: ketoconazole, itraconazole, posaconazole, and voriconazole telithromycin and clarithromycin Co-administration of fluconazole increased ivacaftor exposure (AUC) by 3.0-fold. Simulation suggested co-administration with fluconazole, a moderate CYP3A inhibitor, may increase tezacaftor exposure (AUC) by approximately 2.0-fold.

Tezacaftor And Ivacaftor + Ketoconazole🟡Moderate

Tezacaftor And Ivacaftor + Ciprofloxacin🟢Minor

No significant effect on tezacaftor or ivacaftor exposure; no dosage adjustment necessary.

Tezacaftor And Ivacaftor + Midazolamℹ️Unknown

Potential for tezacaftor/ivacaftor to affect other drugs 7.4 CYP3A Substrates Co-administration of SYMDEKO with midazolam (oral), a sensitive CYP3A substrate, did not affect midazolam exposure.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.